Management of antipsychotic treatment discontinuation and interruptions using model-based simulations

Clinical Pharmacology: Advances and Applications

Volumn 4, Issue 1, 2012, Pages 25-40

  Samtani, Mahesh N ^a   Sheehan, John J ^a   Fu, Dong Jing ^a   Remmerie, Bart ^b   Sliwa, Jennifer Kern ^a   Alphs, Larry ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Long acting injection; Nonadherence; Paliperidone palmitate; Pharmacokinetics; Plasma concentrations; Risperidone

Indexed keywords

LONG ACTING DRUG; NEUROLEPTIC AGENT; PALIPERIDONE; RISPERIDONE; SUSTENNA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED DRUG RELEASE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG WITHDRAWAL; PATIENT COMPLIANCE; RETREATMENT; SCHIZOPHRENIA; SIMULATION; STEADY STATE;

EID: 84930480568     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S32735     Document Type: Article

References (35)

1. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psych. 2004;161(2 Suppl):1-56.
2. Kane JM. Treatment adherence and long-term outcomes. CNS Spectrums. 2007;12(10 Suppl 17):21-26.
3. Marshall M, Rathbone J. Early intervention for psychosis. Cochrane Database Syst Rev. 2006;6:CD004718.
4. Bhanji H, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol. 2004;14:87-92.
5. Masand PS, Roca M, Turner MS, Kane JM. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry. 2009;11:147-154.
6. Weiden PJ, Zygmunt A. The road back: working with the severely mentally ill. Medication noncompliance in schizophrenia. J Pract Psychiatr Behav Health. 1997;3:106-110.
7. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168:603-609.
8. Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry. 2008;8:32-39.
9. Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry. 2003;64 Suppl 16:14-17.
10. Kozma CM, Slaton T, Dirani R, Gopal S, Fastenau J, Hough D. Changes in schizophrenia-related health care resource utilization among patients receiving paliperidone palmitate: results of a 52-week clinical trial. Curr Med Res Opin. 2011;27:1603-1611.
11. Subotnik KL, Nuechterlein KH, Ventura J, et al. Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry. 2011;168:286-292.
12. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55:886-891.
13. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry. 2003;64:1308-1315.
14. Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry. 2009;195:63-67.
15. Robinson DG. Medication adherence and relapse in recent-onset psychosis. Am J Psychiatry. 2011;168:240-242.
16. Zhu B, Ascher-Svanum H, Shi L, Faries D, Montgomery W, Marder SR. Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatr Serv. 2008;59:315-317.
17. Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007;27:6-14.
18. Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116:107-117.
19. Markowitz M, Turkoz I, Fu DJ, et al. Post hoc comparative effectiveness study of paliperidone palmitate vs paliperidone ER: an indirect comparison from placebo-controlled relapse prevention studies. Presented at the American College of Neuropsychopharmacology 49th Annual Meeting, December 5-9, 2010, Miami Beach, FL.
20. Wilson WH. A visual guide to expected blood levels of long-acting injectable risperidone in clinical practice. J Psychiatr Pract. 2004;10:393-401.
21. Risperdal® (risperidone, full prescribing information). Titusville, FL: Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals Inc; 2011.
22. Invega® (paliperidone, full prescribing information) Titusville, FL: Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals Inc; 2011.
23. Boom S, Talluri K, Janssens L, et al. Single-and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. J Clin Pharmacol. 2009;49:1318-1330.
24. Cirincione B, Redman M, Fiedler-Kelley J, Ludwig E, Vermeulen A. Population pharmacokinetics of paliperidone ER in healthy subjects and patients with schizophrenia. Clin Pharmacol Ther. 2007;81:S19.
25. Thyssen A, Vermeulen A, Fuseau E, Fabre MA, Mannaert E. Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders. Clin Pharmacokinet. 2010;49:465-478.
26. Risperdal® Consta® (risperidone, full prescribing information.) Titusville, FL: Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals Inc; 2011.
27. Gefvert O, Eriksson B, Persson P, et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal® Consta®) in patients with schizophrenia. Int J Neuropsychopharmacol. 2005;8:27-36.
28. Samtani A, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly long-acting formulation of atypical antipsychotic. Clin Pharmacokinet. 2009;48:585-600.
29. Invega® Sustenna® (paliperidone palmitate) extended-release injectable suspension prescribing information. Titusville, NJ: Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals Inc; 2011.
30. Cleton A, Rossenu S, Hough D, et al. Assessment of the dose proportionality of paliperidone palmitate 25, 50, 100, and 150mg eq. A new long-acting injectable antipsychotic following administration in the deltoid or gluteal muscles. Clin Pharmacol Ther. 2008;83:S31.
31. Bishara D. Once-monthly paliperidone injection for the treatment of schizophrenia. Neuropsychiatr Dis Treat. 2010;6:561-572.
32. Eerdekens M, Karcher K, Remmerie B, et al. Pharmacokinetics and tolerability of long-acting injectable risperidone in schizophrenia. Schizophr Res. 2004;70:91-100.
33. Product monograph. Invega® Sustenna® paliperidone palmitate prolonged-release injectable suspension. Toronto, Ontario: Janssen-Ortho Inc; 2010.
34. Samtani MN, Gopal S, Gassmann-Mayer C, Alphs L, Palumbo JM. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modeling and clinical trial data. CNS Drugs. 2011;25:829-845.
35. Sheehan JJ, Reilly KR, Fu DJ, Alphs L. Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents. Poster 126 presented at 23rd Annual US Psychiatric and Mental Health Congress Conference and Exhibition, November 18-21, 2010, Orlando, FL.